Alemtuzumab Efficacy and Safety Were Maintained over 8 Years in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease from Care-Ms I: Topaz Study Follow-Up
AuthID
P-00R-46N
P-00R-46N